Company intelligence / Profile preview

Chek Diagnostics

Isfiya, Israel

Ownership: Private
Employees: ~85
Development stage: Other

Overview

Developing non-invasive, preparation-free ingestible imaging capsule (C-Scan) for colorectal cancer screening via low-dose X-ray detection of polyps. CE Mark approved in 2015 for Europe; U.S. pivotal study initiated in 2017 but paused in 2021 due to COVID-19.

Therapeutic areas: Oncology
Industry: Medical Imaging

Beyond the preview

Go deeper on Chek Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chek Diagnostics.

Explore the full profile